PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26221N0039Eliglustat medication PERIOD of performance: 10 — Genzyme Corp

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Sep 30, 2021 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

262-Network Contract Office 22l (36C262)

Awarding office

Genzyme Corp

Recipient

Sep 30, 2021

PoP end

$44K

Obligated

$265K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Genzyme Corp — $90

Contract facts

Federal

Contract number36C26221N0039

Also listed as36C262-21-N-0039

Also listed as36F79719D0153-36C26221N0039

Agency262-Network Contract Office 22l (36C262)

Awarding office262-Network Contract Office 22l (36C262)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentGenzyme Corp

CAGE1HBD8

UEIX2XMAQLR9DA8

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79719D0153

Place of performanceDEERFIELD IL

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startOct 1, 2020

PoP end (current)Sep 30, 2021

Obligated$44K

Current value$265K

Potential value$265K

ELIGLUSTAT MEDICATION PERIOD OF PERFORMANCE: 10/1/2020 TO 9/30/2021 is a federal award for 262-Network Contract Office 22l (36C262) held by Genzyme Corp. Estimated value $265K ($44K obligated). Current period of performance ends Sep 30, 2021. Last award drew 1 bidder. Place of performance: DEERFIELD IL.

ELIGLUSTAT MEDICATION PERIOD OF PERFORMANCE: 10/1/2020 TO 9/30/2021

Recompete timing

Public

● Past PoP end (1786 days ago)

Current PoP ended Sep 30, 2021 (1786 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26221N0039?

36C26221N0039 (Eliglustat medication PERIOD of performance: 10) is a 262-Network Contract Office 22l (36C262) award with a potential value of $265K, currently held by Genzyme Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C262-21-N-0039?

36C262-21-N-0039 is the dashed form of PIID 36C26221N0039 (Eliglustat medication PERIOD of performance: 10), held by Genzyme Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26221N0039?

262-Network Contract Office 22l (36C262) awarded 36C26221N0039 to Genzyme Corp (potential $265K).

Who is the incumbent on 36C26221N0039?

Genzyme Corp is the incumbent. The current period of performance ends Sep 30, 2021.

When does Genzyme Corp’s 36C26221N0039 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2021. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Oct 1, 2021 · refreshed monthly